13 – MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS
暂无分享,去创建一个
[1] J. Kehne,et al. 3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site. , 1992, Journal of medicinal chemistry.
[2] H. Zilch,et al. Sila-substitution--a useful strategy for drug design? , 1986, Endeavour.
[3] G. W. Anderson,et al. Antihistamine agents; halogenated N,N-dimethyl-N-benzyl-N-(2-pyridyl)-ethylenediamines. , 1949, The Journal of organic chemistry.
[4] R. C. Young,et al. Dipole moment in relation to H2 receptor histamine antagonist activity for cimetidine analogues. , 1986, Journal of medicinal chemistry.
[5] D. Liston,et al. Syntheses, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 8-carbaphysostigmine analogues. , 1992, Journal of medicinal chemistry.
[6] E G McMahon,et al. Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists. , 1993, Journal of medicinal chemistry.
[7] E. Imamiya,et al. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. , 1996, Journal of medicinal chemistry.
[8] J. Fauchère. Elements for the rational design of peptide drugs , 1986 .
[9] A. Kozikowski,et al. Structure-activity relationship studies of cocaine: replacement of the C-2 ester group by vinyl argues against H-bonding and provides an esterase-resistant, high-affinity cocaine analogue. , 1992, Journal of medicinal chemistry.
[10] M. Parnham,et al. Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions. , 1987, Biochemical pharmacology.
[11] J. Watkins,et al. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. , 1990, Trends in pharmacological sciences.
[12] H. Grimm. Zur Systematik der chemischen Verbindungen vom Standpunkt der Atomforschung, zugleich über einige Aufgaben der Experimentalchemie , 1929, Naturwissenschaften.
[13] H. Lönnberg,et al. Synthesis and pharmacological properties of 4(5)-(2-ethyl-2,3-dihydro-2 silainden-2-yl)imidazole, a silicon analogue of atipamezole , 1996 .
[14] P. Anderson,et al. N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist. , 1985, Journal of medicinal chemistry.
[15] J. Désiré,et al. (Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors. , 1995, Journal of medicinal chemistry.
[16] W. Landauer,et al. ON THE ROLE OF RIBOFLAVIN IN THE TERATOGENIC ACTIVITY OF BORIC ACID. , 1964, The Journal of experimental zoology.
[17] Ralph Hirschmann,et al. Design, synthesis, and crystal structure of a pyrrolinone-based peptidomimetic possessing the conformation of a .beta.-strand: potential application to the design of novel inhibitors of proteolytic enzymes , 1992 .
[18] I Yanagisawa,et al. Histamine H2 receptor antagonists. 1. Synthesis of N-cyano and N-carbamoyl amidine derivatives and their biological activities. , 1984, Journal of medicinal chemistry.
[19] P. Krogsgaard‐Larsen. gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. , 1981, Journal of medicinal chemistry.
[20] J. Drummond,et al. Convenient procedure for the preparation of alkyl and aryl substituted N-(aminoalkylacyl)sulfonamides , 1988 .
[21] J. Kardos,et al. Octahydroindolo[2,3-a]quinolizin-2-one, a novel structure for γ-aminobutyric acid (GABA) uptake inhibition , 1986 .
[22] R. Hirschmann,et al. An effective synthesis of scalemic 3,5,5-trisubstituted pyrrolin-4-ones , 1993 .
[23] C. B. Naylor,et al. Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. , 1992, Journal of medicinal chemistry.
[24] T. Willson,et al. Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives. , 1992, Journal of medicinal chemistry.
[25] J S Ward,et al. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines . , 1992, Journal of medicinal chemistry.
[26] Aalt Bast,et al. Comprehensive medicinal chemistry , 1991 .
[27] B. T. Phillips,et al. Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists. , 1982, Journal of medicinal chemistry.
[28] R. D. Dyer,et al. Hydroxamic acid inhibitors of 5-lipoxygenase. , 1987, Journal of medicinal chemistry.
[29] H. Erlenmeyer,et al. Zusammenhänge zwischen Konstitution und Wirkung bei Pyrazolonderivaten , 1935 .
[30] T. Honoré,et al. Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships. , 1991, Journal of medicinal chemistry.
[31] E. Browning. Toxicity of Industrial Metals , 1961 .
[32] P. Contreras,et al. Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide. , 1992, Journal of medicinal chemistry.
[33] M. Drysdale,et al. Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. , 1992, Journal of medicinal chemistry.
[34] R. Barth,et al. Boron compounds for neutron capture therapy. , 1989, Basic life sciences.
[35] J. Kraus. Isosterism and molecular modification in drug design: new n-dipropylacetate analogs as inhibitors of succinic semi aldehyde dehydrogenase. , 1983, Pharmacological research communications.
[36] A. Sleight,et al. Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. , 1997, Journal of medicinal chemistry.
[37] L L Iversen,et al. Novel quinuclidine-based ligands for the muscarinic cholinergic receptor. , 1990, Journal of medicinal chemistry.
[38] R. McGuire,et al. Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments. , 1996, Journal of medicinal chemistry.
[39] F. Lichtenthaler,et al. Intermediates in the Formation of γ‐Pyrones from Hexose Derivatives: A Simple Synthesis of Kojic Acid and Hydroxymaltol , 1969 .
[40] C. Lipinski,et al. Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors. , 1992, Journal of medicinal chemistry.
[41] T. Goodson,et al. Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. , 1987, Journal of medicinal chemistry.
[42] Luis Carrasco,et al. Synthesis and antiviral evaluation of nucleosides of 5-methylimidazole-4-carboxamide. , 1985, Journal of Medicinal Chemistry.
[43] T. Burke,et al. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. , 2000, Journal of medicinal chemistry.
[44] J. Kraus,et al. Isosterism and molecular modification in drug design: tetrazole analogue of GABA: effects on enzymes of the gamma-aminobutyrate system. , 1983, Pharmacological research communications.
[45] W. Landauer,et al. On the chemical production of developmental abnormalities and of phenocopies in chicken embryos. , 1954, Journal of cellular physiology. Supplement.
[46] H. Fischer,et al. A novel biologically active selenoorganic compound. VIII. Biotransformation of ebselen. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.
[47] P. Krogsgaard‐Larsen,et al. Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure–Activity Relationships and Therapeutic Potential , 1988 .
[48] B. Matthews,et al. Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin. , 1989, Biochemistry.
[49] R. Chang,et al. Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles. , 1993, Journal of medicinal chemistry.
[50] C G Wermuth,et al. Aminopyridazines--an alternative route to potent muscarinic agonists with no cholinergic syndrome. , 1993, Farmaco.
[51] J. Dunitz,et al. Structure of boromycin. , 1971, Helvetica chimica acta.
[52] B. Roques,et al. Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues , 1988 .
[53] E. Grant,et al. The dipole moments of 1,3-dimethylthiourea, 1,3-dimethyl-2-cyanoguanidine and 1,1-bis-methylamino-2-nitroethene in a aqueous solution , 1982 .
[54] C. Wermuth,et al. Analogues tétrazoliques d'agents GABA-mimétiques , 1984 .
[55] J. Hawkinson,et al. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines. , 1999, Journal of medicinal chemistry.
[56] G Bolliger,et al. Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor. , 1992, Journal of medicinal chemistry.
[57] R. Passmore,et al. BIOCHEMICAL LESIONS AND LETHAL SYNTHESIS , 1964 .
[58] R. Winneker,et al. Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. , 1992, Journal of medicinal chemistry.
[59] D. Binder,et al. Thiophen als Strukturelement physiologisch aktiver Substanzen, 16. Mitt. Thienoisoxazole durch Substitution am Oximstickstoff , 1987 .
[60] M. Reich,et al. Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. , 1983, Journal of medicinal chemistry.
[61] H. Nagasawa,et al. Acyl, N-protected alpha-aminoacyl, and peptidyl derivatives as prodrug forms of the alcohol deterrent agent cyanamide. , 1986, Journal of medicinal chemistry.
[62] D. Junquéro,et al. Design and synthesis of new hypocholesterolemic organosilanes with antioxidant properties , 1996 .
[63] J. Büchi,et al. Über lokalanästhetisch wirksame basische Ester und Amide verschiedener Alkoxy-amino-benzoesäuren , 1951 .
[64] A. Jeng,et al. Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11 , 1997 .
[65] W. S. Sheldrick,et al. Sila-Pharmaka, XIX. Sila-Pridinol und Pridinol: Darstellung und Eigenschaften sowie Strukturen im kristallinen und gelösten Zustand , 1980 .
[66] Gabriele Cruciani,et al. A New Set of Principal Properties for Heteroaromatics Obtained by GRID , 1996 .
[67] E. Grant,et al. The dielectric properties of seven polar amidine-containing compounds of biological interest , 1985 .
[68] J. Katzenellenbogen,et al. Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase. , 1985, Journal of medicinal chemistry.
[69] Thierry Langer,et al. New Principal Components Derived Parameters Describing Molecular Diversity of Heteroaromatic Residues , 1998 .
[70] Fessenden Rj,et al. The biological properties of silicon compounds. , 1967 .
[71] K. H. Lee,et al. Comparison of analgesic effects of isosteric variations of salicylic acid and aspirin (acetylsalicylic acid) , 1975 .
[72] L. H. Sommer,et al. STEREOCHEMISTRY OF HYDRIDE ION DISPLACEMENT FROM SILICON. ENHANCED RATES AT BRIDGEHEAD AND 4-RING SILICON ATOMS1 , 1957 .
[73] A. S. Chawla,et al. Medicinal chemistry of tetrazoles. , 1980, Progress in medicinal chemistry.
[74] A. Larsen,et al. A New Bio-isostere : Alkylsulphonamidophenethanolamines , 1964, Nature.
[75] Christopher M Thomas,et al. Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one. , 1992, Journal of medicinal chemistry.
[76] Y. Pommier,et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. , 2000, Journal of medicinal chemistry.
[77] J. Deeter,et al. Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor. , 1987, Journal of medicinal chemistry.
[78] W. Kinney,et al. Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists. , 1992, Journal of medicinal chemistry.
[79] W. Günther,et al. Organic selenium compounds: their chemistry and biology. , 1973 .
[80] D. Anderson,et al. Ligands for brain cholinergic channel receptors: synthesis and in vitro characterization of novel isoxazoles and isothiazoles as bioisosteric replacements for the pyridine ring in nicotine. , 1994, Journal of medicinal chemistry.
[81] Y. Masuda,et al. Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. , 1979, Journal of medicinal chemistry.
[82] R. Bergeron,et al. Structural alterations in desferrioxamine compatible with iron clearance in animals. , 1992, Journal of Medicinal Chemistry.
[83] Paul A. Bartlett,et al. Differential binding energy: a detailed evaluation of the influence of hydrogen-bonding and hydrophobic groups on the inhibition of thermolysin by phosphorus-containing inhibitors , 1991 .
[84] R. Franke,et al. Discriminant--analytical investigation on the structural dependence of hyperglycemic and hypoglycemic activity in a series of substituted o-toluenesulfonylthioureas and o-toluenesulfonylureas. , 1979, Journal of medicinal chemistry.
[85] D. R. Curtis,et al. Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection. , 1991, Journal of medicinal chemistry.
[86] H. Köhler,et al. Dicyanmethanido‐ und Cyanamido‐oxoanionen. Untersuchungen zum sauerstoffanalogen Charakter der C(CN)2‐ und NCN‐Gruppen , 1970 .
[87] S. Hibi,et al. Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives. , 2000, Journal of medicinal chemistry.
[88] M. B. Chenoweth,et al. ON THE MECHANISMS OF THE PHARMACOPHORIC EFFECT OF HALOGENATION. , 1963, Pharmacological reviews.
[89] P. Wyman,et al. 7-Aroyl-2,3-dihydrobenzo[b]furan-3-carboxylic acids and 7-benzoyl-2,3-dihydrobenzo[b]thiophene-3-carboxylic acids as analgesic agents. , 1986, Journal of medicinal chemistry.
[90] I. Langmuir. ISOMORPHISM, ISOSTERISM AND COVALENCE. , 1919 .
[91] A. Jeng,et al. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme. , 1998, Journal of medicinal chemistry.
[92] P. Goldman. The carbon-fluorine bond in compounds of biological interest. , 1969, Science.
[93] Christopher A. Lipinski,et al. Chapter 27. Bioisosterism in Drug Design , 1986 .
[94] J. Rokach,et al. Kojic amine--a novel gamma-aminobutyric acid analogue. , 1979, Journal of medicinal chemistry.
[95] B. Lipworth. Leukotriene-receptor antagonists , 1999, The Lancet.
[96] C. Thornber,et al. Isosterism and molecular modification in drug design , 1979 .
[97] T. Burke,et al. Preparation of fluoro- and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogs of O-phosphotyrosine , 1993 .
[98] C. Jennings-White,et al. Synthesis and biological activity of carboxylic acid replacement analogues of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline. , 1985, Journal of medicinal chemistry.